A citation-based method for searching scientific literature

Peng Li, Jieru E Lin, Adam E Snook, Scott A Waldman. Toxins (Basel) 2017
Times Cited: 8



K Shailubhai, H H Yu, K Karunanandaa, J Y Wang, S L Eber, Y Wang, N S Joo, H D Kim, B W Miedema, S Z Abbas, S S Boddupalli, M G Currie, L R Forte. Cancer Res 2000
Times Cited: 170




List of shared articles



Times cited

Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies.
John C Flickinger, Jeffrey A Rappaport, Joshua R Barton, Trevor R Baybutt, Amanda M Pattison, Adam E Snook, Scott A Waldman. Biomark Med 2021
0

Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity.
Amanda M Pattison, Joshua R Barton, Ariana A Entezari, Alicja Zalewski, Jeff A Rappaport, Adam E Snook, Scott A Waldman. Cancer Biol Ther 2020
5

An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Jeffrey A Rappaport, Scott A Waldman. Expert Rev Clin Pharmacol 2020
1


GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer.
Amanda N Lisby, John C Flickinger, Babar Bashir, Megan Weindorfer, Sanjna Shelukar, Madison Crutcher, Adam E Snook, Scott A Waldman. Expert Rev Precis Med Drug Dev 2021
0

APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.
Erik S Blomain, Jeffrey A Rappaport, Amanda M Pattison, Babar Bashir, Ellen Caparosa, Jonathan Stem, Adam E Snook, Scott A Waldman. Cancer Biol Ther 2020
5